文献速递临床试验与 GCP

多中心、随机、开放标签、盲法终点评估试验:皮质类固醇联合静脉注射免疫球蛋白(IVIG)和阿司匹林对比单用IVIG和阿司匹林预防川崎病(KD)冠状动脉瘤(CAA):KD-CAA预防(KD-CAAP)试验方案

Multi-centre, randomised, open-label, blinded endpoint assessed, trial of corticosteroids plus intravenous immunoglobulin (IVIG) and aspirin, versus IVIG and aspirin for prevention of coronary artery aneurysms (CAA) in Kawasaki disease (KD): the KD CAA prevention (KD-CAAP) trial protocol.
PubMed 文献 · Trials · 2023-01-26

KD-CAAP是一项在欧洲开展的多中心、随机、开放标签、盲法终点评估试验,计划将未选择的川崎病(KD)患者按1:1随机分配至口服泼尼松龙2 mg/kg/天联合标准治疗IVIG(2 g/kg)和阿司匹林(40 mg/kg/天)组,或单用IVIG和阿司匹林组。共同主要结局为3个月随访内任何冠状动脉瘤(CAA)及第1、2、6周最大冠状动脉Z评分的平均估计值(校正补救治疗后)。

要点

  • KD-CAAP试验检验在标准治疗IVIG和阿司匹林基础上立即联合皮质类固醇能否降低未选择KD患者的CAA发生率。
  • 患者按1:1随机接受口服泼尼松龙2 mg/kg/天联合IVIG(2 g/kg)和阿司匹林(40 mg/kg/天),或单用IVIG和阿司匹林。
  • 共同主要结局为3个月随访内任何CAA及第1、2、6周最大冠状动脉Z评分平均估计值(校正补救治疗)。

核心结论

  • KD-CAAP试验将检验在标准治疗IVIG和阿司匹林基础上立即联合皮质类固醇能否降低未选择KD患者的CAA发生率。
  • 若发现皮质类固醇可预防CAA且安全,这将是廉价且广泛可及的干预措施,可立即用于儿童。

研究设计与样本

  • 多中心、随机、对照、开放标签、盲法终点评估试验,由conect4children泛欧洲临床试验网络支持,在欧洲开展。
  • 符合入选标准的KD患者按1:1随机分配至口服泼尼松龙2 mg/kg/天联合标准治疗IVIG(2 g/kg)和阿司匹林(40 mg/kg/天)组,或单用IVIG和阿司匹林组。
  • 进一步管理由体温和C反应蛋白(CRP)反应决定。

主要发现

  • 共同主要结局为3个月试验随访内任何CAA,以及第1、2、6周最大冠状动脉Z评分的平均估计值(校正补救治疗后)。
  • 还将评估成本效果、生活质量、皮质类固醇毒性及其他安全性结局。

关键数值与推荐

  • 口服泼尼松龙2 mg/kg/天联合标准治疗IVIG(2 g/kg)和阿司匹林(40 mg/kg/天)。
  • 单用IVIG(2 g/kg)和阿司匹林(40 mg/kg/天)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Kawasaki disease (KD) is an acute self-limiting inflammatory vasculitis affecting predominantly medium-sized arteries, particularly the coronary arteries. A number of recent studies conducted in different European countries have demonstrated alarmingly high coronary complications despite treatment with intravenous immunoglobulin (IVIG). These high complication rates now emphasize the need for an urgent reappraisal of IVIG as the sole primary therapeutic agent for KD. The Kawasaki disease CAA prevention (KD-CAAP) trial will test the hypothesis that immediate adjunctive corticosteroid treatment to standard of care IVIG and aspirin will reduce coronary artery aneurysm (CAA) rates in unselected KD patients across Europe. METHODS: KD-CAAP is a multicentre, randomised, controlled, open-label, blinded endpoint assessed trial that will be conducted across Europe supported by the conect4children pan-European clinical trials network. Patients with KD who satisfy the eligibility criteria will be randomised (1:1) to receive either oral prednisolone 2 mg/kg/day plus standard of care therapy IVIG (2 g/kg) and aspirin (40 mg/kg/day); or IVIG and aspirin alone. Further management is dictated by temperature and C-reactive protein (CRP) responses. Co-primary outcomes are as follows: (i) any CAA within the 3 months of trial follow-up; (ii) average estimate of maximum coronary Z-score at weeks 1, 2 and 6 adjusting for rescue treatment. Additional outcomes will be assessed including cost effectiveness, quality of life, corticosteroid toxicity and other safety outcomes. DISCUSSION: Several recent studies have indicated that coronary complications associated with KD across Europe are much higher than early trials of IVIG had initially suggested. KD-CAAP directly addresses this issue by exploring the therapeutic benefit of adjunctive corticosteroids in unselected KD cases. If we find that corticosteroids prevent CAA and are safe, this is a cheap and widely available intervention that could be implemented immediately for the benefit of children. TRIAL REGISTRATION: ISRCTN71987471- March 31, 2020; Eudract 2019-004433-17.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Eleftheriou D, Moraes YC, Purvis C, et al. Multi-centre, randomised, open-label, blinded endpoint assessed, trial of corticosteroids plus intravenous immunoglobulin (IVIG) and aspirin, versus IVIG and aspirin for prevention of coronary artery aneurysms (CAA) in Kawasaki disease (KD): the KD CAA prevention (KD-CAAP) trial protocol. Trials. 2023. PMID: 36703139. doi:10.1186/s13063-022-07051-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。